Press Releases

Worldwide Ocaliva® net sales of $92.8 million , representing 17% growth over the prior year quarter Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows Non-GAAP adjusted operating expense guidance to $380 to $395 million NASH data generation remains on

Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK -PBC study groups Poster presentations describe a new consensus panel biopsy reading methodology for NASH clinical trials and the study design of

NEW YORK , Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial results prior

NEW YORK , Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief

NEW YORK , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into

NEW YORK , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief

NEW YORK , Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into

Worldwide Ocaliva ® net sales of $96.6 million , representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 million Updates to the

NEW YORK , July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior

New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with obeticholic acid (OCA) In a real-world study of patients with PBC, Ocaliva ® reduced alkaline